Feed BNR
BN

Burning Rock Biotech Limited

BNR · NASDAQ

$12.80 +10.70% (+$1.24)
1M +34.48%
Market Cap ¥90.6M
P/E Ratio -
Div. Yield -
ROE 12.97%
Piotroski F-Score Weak
3/9
Valuation
100 /100
Cheap
P/B 0.18x
P/S 0.18x
P/FFO N/A
Growth
10 /100
Declining
Book val. growth 22.67%
Rev. growth 1.42%
FCF growth N/A
Profitability
20 /100
Weak
Op. margin 12.99%
Gross margin 74.55%
FCF margin 7.88%
Quality
8 /100
Poor
ROA 9.06%
ROIC 12.01%
Asset turnover 0.67x
Debt
69 /100
Low
Int. coverage -1,104.23x
Debt/Equity 0.09x
Current ratio 3.03x
Stability
53 /100
Moderate
EPS volatility 50.71%
Beta 1.39x
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o BNR
Online

O podjetju

Burning Rock Biotech Limited (BNR) is a biotechnology company focused on the development and commercialization of diagnostic tests for oncological diseases. Their products include genetic tests and tests for the detection of tumor biomarkers, which help physicians accurately diagnose and treat cancer. Burning Rock Biotech is known for its ability to integrate advanced technologies such as DNA sequencing and artificial intelligence into its diagnostic tests, enabling rapid and precise diagnosis of cancerous diseases. The company also focuses on developing personalized treatment approaches that improve treatment outcomes for cancer patients. Burning Rock Biotech Limited (BNR) shares could be suitable for investors looking for opportunities in the biotechnology sector with an emphasis on cancer diagnosis and treatment.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Yusheng Han

Employees

667

Headquarters

Guangzhou

Prihajajoči dogodki

17 NOV.

Earnings

Upcoming earnings report

61d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.